RxDoctor Payments Data

Ernesto McCombs, DO

Internal Medicine · Las Vegas, NVNPI 1013974112

Payments from drug & device makers

$1,194in general payments, 2019–2025

Across 17 payments — averaging $70.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$375
  • Novartis$250
  • Teleflex LLC$219
  • Foundation Medicine, Inc.$148
  • AstraZeneca$56
  • Abiomed$53
  • plus $93 from 3 others

What the payments were for

  • Food & beverage$1,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott3$375
Novartis2$250
Teleflex LLC2$219
Foundation Medicine, Inc.1$148
AstraZeneca3$56
Abiomed1$53
Pfizer3$47
Merck1$27
AbbVie1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,194 in reported general payments places this provider in the 75th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$112,229
Medicare patients
278
Services billed
1,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$104,044
JardianceEmpagliflozin40$56,891
TrulicityDulaglutide41$56,536
EliquisApixaban55$54,847
MounjaroTirzepatide38$37,546
JanuviaSitagliptin Phosphate18$20,997
FarxigaDapagliflozin Propanediol11$17,936
DapagliflozinDapagliflozin Propanediol17$16,414
Tresiba Flextouch U-200Insulin Degludec14$7,801
NamzaricMemantine Hcl/Donepezil Hcl13$7,549
Breo ElliptaFluticasone/Vilanterol11$6,056
Rosuvastatin Calcium504$5,546
Levothyroxine Sodium381$5,287
SynthroidLevothyroxine Sodium72$4,790
Metoprolol Succinate277$4,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$54,84755 claims
MerckJanuvia$27$20,99718 claims
AstraZenecaFarxiga$56$17,93611 claims
AbbVieNamzaric, Synthroid$19$12,33985 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →